ArticleJornal de pediatria2026
Incidence study of precocious puberty in the population of the state of Goiás: did the COVID-19 pandemic modify the epidemiology?
Article in Jornal de pediatria, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the incidence and epidemiological, clinical, and laboratory characteristics of Central Precocious Puberty (CPP) before, during, and after the COVID-19 pandemic in Goiás, Brazil.
methodThis retrospective, longitudinal, observational study with a quantitative approach was conducted in Goiás using administrative records of high-cost medication dispensing. All patients registered in the state dispensing center who initiated treatment between 2018 and 2023 were included. Data were analyzed using the Statistical Package for Social Sciences (IBM Corporation, Armonk, USA), version 26.0. Statistical significance was set at 5% (p < 0.05).
resultsA total of 910 CPP treatment requests were evaluated, including 153 before the pandemic, 390 during 2020-2021, and 367 during 2022-2023. This corresponded to increases of 154% and 140% during the pandemic and post-pandemic periods, respectively (p < 0.001). From 2020 onward, patients started gonadotropin-releasing hormone analog therapy at younger ages (104.84 ± 12.52 vs. 107.17 ± 13.42 months; p = 0.027), but showed more advanced pubertal development, with higher Tanner stages (B/G stage 4: 15.9% and 21.4% vs. 8.6%; p = 0.035) and higher stimulated LH levels (22.39 ± 16.81 and 24.64 ± 22.13 vs. 19.87 ± 18.08 mIU/mL; p = 0.046).
conclusionsCPP incidence increased significantly in Goiás during and after the COVID-19 pandemic. Patients also presented more advanced clinical and laboratory features than those diagnosed before the pandemic.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.